Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Kadmon Corporation, LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners and 5 art units, indicating separate examination channels across the portfolio.
HASTINGS, ALISON AZAR is the listed busiest examiner, with 1 pending matter. Since no examiner has a recurring assignment in the provided data, counsel should organize work by application and art unit while coordinating common technical positions where appropriate.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| KOSTURKO, GEORGE W | 1 | 54.6% | +49.0% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 132d overdue |
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | — |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 132d overdue |
| 18059548 | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins | LU, CHENG | 11d overdue |
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | — |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | — |
| 16812867 | IMMUNOMODULATORY AGENTS | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| 1626 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | 1627 | §102§103§112 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 1626 | §102§103§112 | Non-Final OA | 132d overdue | Pending | Feb 01, 2023 |
| 18059548 | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins | LU, CHENG | 1642 | §112 | Non-Final OA | 11d overdue | Pending | Nov 29, 2022 |
| 16812867 | IMMUNOMODULATORY AGENTS | GAO, ASHLEY HARTMAN | 1678 | §103Other | Final Rejection | — | Pending | Mar 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKadmon Corporation, LLC has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Alison Azar Hastings has the most, with 1 of Kadmon Corporation, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
